Literature DB >> 7277422

'Pseudo-dominant' inheritance in Friedreich's ataxia.

A E Harding, K J Zilkha.   

Abstract

A family is described in which Friedreich's ataxia occurred in two generations. It is proposed that this resulted from a homozygote-heterozygote mating. The heterozygote frequency for the Friedreich's ataxia gene is in the order of 1 in 110, so the likelihood of the disease developing in an individual child of a patient is 1 in 220. This risk is probably higher than that often assumed when counselling patients with this disorder.

Entities:  

Mesh:

Year:  1981        PMID: 7277422      PMCID: PMC1048733          DOI: 10.1136/jmg.18.4.285

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  4 in total

1.  Clinical description and roentgenologic evaluation of patients with Friedreich's ataxia.

Authors:  G Geoffroy; A Barbeau; G Breton; B Lemieux; M Aube; C Leger; J P Bouchard
Journal:  Can J Neurol Sci       Date:  1976-11       Impact factor: 2.104

2.  Cardiac aspects of Friedreich's ataxia.

Authors:  S H BOYER; A W CHISHOLM; V A McKUSICK
Journal:  Circulation       Date:  1962-03       Impact factor: 29.690

3.  An electrophysiological and pathological study of peripheral nerves in Friedreich's ataxia.

Authors:  J G McLeod
Journal:  J Neurol Sci       Date:  1971-03       Impact factor: 3.181

4.  Genetic and family studies in Friedreich's ataxia.

Authors:  E Andermann; G M Remillard; C Goyer; L Blitzer; F Andermann; A Barbeau
Journal:  Can J Neurol Sci       Date:  1976-11       Impact factor: 2.104

  4 in total
  14 in total

1.  Early onset of Friedreich's ataxia in a compound heterozygote.

Authors:  M C McGovern; M Stewart; P J Morrison; D Webb; S Hawkins
Journal:  Arch Dis Child       Date:  2000-07       Impact factor: 3.791

Review 2.  Friedreich ataxia: an overview.

Authors:  M B Delatycki; R Williamson; S M Forrest
Journal:  J Med Genet       Date:  2000-01       Impact factor: 6.318

3.  Diagnosing Friedreich's ataxia.

Authors:  N W Wood
Journal:  Arch Dis Child       Date:  1998-03       Impact factor: 3.791

4.  Efficacy and Tolerability of Interferon Gamma in Treatment of Friedreich's Ataxia: Retrospective Study.

Authors:  Mehmet Fatih Yetkİn; Murat GÜltekİn
Journal:  Noro Psikiyatr Ars       Date:  2020-09-21       Impact factor: 1.339

5.  Determination of Genotypic and Phenotypic Characteristics of Friedreich's Ataxia and Autosomal Dominant Spinocerebellar Ataxia Types 1, 2, 3, and 6.

Authors:  Pınar Bengi Boz; Filiz Koç; Sabriye Kocatürk Sel; Ali İrfan Güzel; Halil Kasap
Journal:  Noro Psikiyatr Ars       Date:  2016-06-01       Impact factor: 1.339

Review 6.  Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities.

Authors:  Renata Santos; Sophie Lefevre; Dominika Sliwa; Alexandra Seguin; Jean-Michel Camadro; Emmanuel Lesuisse
Journal:  Antioxid Redox Signal       Date:  2010-09-01       Impact factor: 8.401

7.  Preclinical and manifest diabetes mellitus in young patients with Friedreich's ataxia: no evidence of immune process behind the islet cell destruction.

Authors:  E J Schoenle; E J Boltshauser; S Baekkeskov; M Landin Olsson; T Torresani; A von Felten
Journal:  Diabetologia       Date:  1989-06       Impact factor: 10.122

8.  Perceived effectiveness and barriers to physical therapy services for families and children with Friedreich ataxia.

Authors:  Joyce Maring; Earllaine Croarkin; Sylvia Morgan; Margaret Plack
Journal:  Pediatr Phys Ther       Date:  2013       Impact factor: 3.049

9.  'Pseudo-Dominant' Inheritance in Friedreich's Ataxia: Clinical and Genetic Study of a Brazilian Family.

Authors:  Adriana Moro; Alberto R M Martinez; Simone C V Karuta; Renato P Munhoz; Mariana Moscovich; Francisco M B Germiniani; Walter O Arruda; Salmo Raskin; Hélio A G Teive
Journal:  Mov Disord Clin Pract       Date:  2014-09-30

10.  Long range regulation of human FXN gene expression.

Authors:  Novita Puspasari; Simone M Rowley; Lavinia Gordon; Paul J Lockhart; Panos A Ioannou; Martin B Delatycki; Joseph P Sarsero
Journal:  PLoS One       Date:  2011-07-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.